Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Haematology International Journal Research Article 22 min read

Clinical Implications of Neutrophil-to-Lymphocyte Ratio in Sickle Cell Disease

Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu*
* Corresponding author
ISSN: 2578-501X  10.23880/hij-16000242  Received: February 13, 2024  Published: March 12, 2024
 — views
 90 references
PDF
Keywords
Sickle Cell Anemia Neutrophil Lymphocyte Neutrophil to Lymphocyte Ratio Inflammation Biomarkers
Abstract

Sickle Cell Disease (SCD) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia and vaso-occlusive events. In recent years, the Neutrophil-to-Lymphocyte Ratio (NLR) has emerged as a potential biomarker with prognostic and diagnostic significance in various medical conditions. This review explores the clinical implications of NLR in the context of SCD, shedding light on its role as a valuable indicator of inflammation, disease severity, and treatment response. The inflammatory state is a key contributor to the pathophysiology of SCD, influencing disease progression and complications. NLR, calculated from routine complete blood counts, reflects the balance between the immune response’s cellular components and has been implicated in assessing the inflammatory status in various diseases. In the context of SCD, elevated NLR has been associated with increased vaso-occlusive events, suggesting its potential utility as a predictive marker for disease complications. In conclusion, this perspective review consolidates current knowledge on the clinical implications of NLR in Sickle Cell Disease. It highlights the potential of NLR as a readily available and cost-effective biomarker for assessing inflammation, predicting disease severity, and monitoring treatment response in individuals with SCD. As the understanding of the immunological aspects of SCD continues to evolve, NLR stands out as a promising parameter that may contribute to a more comprehensive approach to managing this complex hematologic disorder.

Emmanuel Ifeanyi Obeagu1* and Getrude Uzoma Obeagu2

approach to managing this complex hematologic disorder.

Introduction

Sickle cell anemia, an autosomal recessive genetic disorder, results from a mutation in the beta-globin gene [1, 2, 3, 4]. This mutation leads to the production of abnormal hemoglobin (HbS), which causes red blood cells to assume a characteristic sickle shape [5, 6, 7]. Individuals with SCA experience chronic anemia, vaso-occlusive crises, and are more susceptible to infections and inflammation [8]. The chronic inflammation observed in SCA is a critical component of the disease, contributing to both acute and chronic complications [9]. Therefore, the identification of biomarkers to assess the inflammatory status in these patients is of great importance [10]. Elevated NLR values have been associated with more severe disease manifestations in SCA, including an increased frequency of vaso-occlusive crises, acute chest syndrome, and other complications [11]. NLR has shown potential in aiding risk stratification and identifying patients who may require more intensive management [12].

SCA patients are particularly susceptible to infections, partly due to impaired immune function [13]. High NLR values have been linked to a higher risk of infection in SCA. Monitoring NLR can help clinicians identify patients at greater risk of infections and implement appropriate preventive strategies [14]. NLR reflects the balance between pro-inflammatory neutrophils and anti-inflammatory lymphocytes [15]. An elevated NLR is indicative of an enhanced inflammatory state in SCA patients [16]. Tracking NLR over time can provide insights into the progression of inflammation and guide treatment decisions [17]. NLR can assist in risk stratification, allowing healthcare providers to identify high-risk patients and tailor treatment plans accordingly [18].

Regular monitoring of NLR can help in the early detection of infections, enabling prompt intervention and reducing morbidity [19]. NLR can guide treatment decisions, especially in the context of anti-inflammatory therapies, by providing valuable information about the patient’s inflammatory status [20]. While the utility of NLR in SCA is promising, more research is needed to establish standardized NLR thresholds and validate its use as a routine clinical tool [21]. Furthermore, longitudinal studies are required to understand the dynamic changes in NLR over time and its correlation with clinical outcomes [22]. The neutrophil-to-lymphocyte ratio is emerging as a valuable biomarker for assessing disease severity, infection risk, and inflammatory status in sickle cell anemia [23]. The integration of NLR into clinical practice has the potential to improve risk stratification, guide treatment decisions, and enhance patient outcomes [24]. Further research is warranted to fully elucidate its clinical applications in the context of SCA.

Neutrophil-to-Lymphocyte Ratio (NLR)

The Neutrophil-to-Lymphocyte Ratio (NLR) is a simple and readily available biomarker derived from complete blood count (CBC) measurements. It has gained increasing recognition as a valuable indicator of systemic inflammation, immune response, and overall health. This review explores the diverse applications of NLR across various medical disciplines and its potential as a versatile tool in clinical practice [25]. The NLR is calculated by dividing the absolute neutrophil count (ANC) by the absolute lymphocyte count (ALC). It serves as a reflection of the balance between innate immunity (neutrophils) and adaptive immunity (lymphocytes). Elevated NLR values are indicative of increased inflammation and have been associated with various pathological conditions [26].

In cardiology, NLR has emerged as a prognostic marker for cardiovascular diseases. Elevated NLR is linked to a higher risk of adverse cardiac events, such as myocardial infarction and heart failure. NLR is now being utilized to aid risk stratification and guide treatment decisions [27, 28, 29]. NLR has shown promise in oncology as a marker of tumor-associated inflammation and overall survival. High NLR values are associated with poorer outcomes in various malignancies, making it a useful tool in cancer prognosis and treatment planning [30, 31]. In infectious diseases, NLR can help distinguish between bacterial and viral infections. An elevated NLR often suggests a bacterial etiology, while a low NLR is more characteristic of viral infections. This differentiation can guide clinicians in selecting appropriate treatments [32, 33]. NLR has relevance in rheumatological conditions, where inflammation plays a central role. It aids in disease activity assessment and monitoring of conditions like rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis [34]. Inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis are characterized by chronic inflammation. NLR can be used to gauge disease activity and predict the risk of flares, aiding in the management of IBD patients [35].

In the intensive care unit (ICU), NLR has proven valuable as a marker for disease severity and outcomes. It can assist in predicting mortality and guiding treatment strategies in critically ill patients [36]. NLR is being investigated in neuroinflammatory conditions, such as multiple sclerosis and neurodegenerative diseases. While still in the research phase, NLR may hold promise as a complementary tool for assessing neuroinflammation [37, 38]. The Neutrophil-to-Lymphocyte Ratio (NLR) is a versatile and easily accessible biomarker with wide-ranging applications in the field of medicine. Its utility spans across multiple specialties, from cardiology and oncology to infectious diseases and rheumatology. NLR provides valuable insights into inflammation, immune response, and disease prognosis, enhancing clinical decision- making and patient care [39, 40]. As research continues to uncover the significance of NLR in various medical contexts, its incorporation into routine clinical practice is poised to grow. The NLR represents a simple yet powerful tool that can aid healthcare professionals in diagnosing and managing of sickle cell anaemia patients [41].

The Utility of Neutrophil-to-Lymphocyte Ratio (NLR) in Sickle Cell Anemia (SCA)

Sickle Cell Anemia (SCA) is a hereditary blood disorder characterized by chronic inflammation and an increased risk of infections [42]. This review examines the emerging role of the Neutrophil-to-Lymphocyte Ratio (NLR) as a valuable biomarker in assessing disease severity and predicting clinical outcomes in individuals with SCA. Sickle Cell Anemia is a genetic disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin (HbS). This results in the deformation of red blood cells into a characteristic sickle shape, causing chronic anemia, vaso- occlusive crises, and susceptibility to infections. Chronic inflammation is a hallmark of SCA, and NLR, as a marker of systemic inflammation, has recently gained attention in the context of this disease [43, 44].

NLR is calculated by dividing the absolute neutrophil count (ANC) by the absolute lymphocyte count (ALC) from a complete blood count (CBC). Neutrophils are key players in innate immunity, while lymphocytes are central to adaptive immunity. An elevated NLR indicates an imbalance between these two immune cell types and is recognized as a sign of systemic inflammation [45]. Elevated NLR values have been associated with more severe clinical manifestations in SCA, including increased frequency and severity of vaso-occlusive crises, acute chest syndrome, and other complications. NLR can serve as a valuable indicator for assessing the overall disease severity in SCA patients, aiding in risk stratification and treatment planning [46]. Individuals with SCA are particularly vulnerable to infections due to their compromised immune function. High NLR values have been linked to a greater susceptibility to infections in these patients. Monitoring NLR can help healthcare providers identify individuals at higher risk of infections and implement proactive preventive measures [47]. NLR serves as a dynamic marker reflecting the inflammatory status in SCA patients. Elevations in NLR may indicate an increase in systemic inflammation, which is a common feature of the disease. Regular NLR monitoring can provide insights into the progression of inflammation over time, helping clinicians make informed treatment decisions [48, 49].

Clinical Implications

NLR can aid in risk stratification, enabling healthcare providers to identify high-risk SCA patients and tailor their treatment plans accordingly [50]. Routine monitoring of NLR can assist in the early detection of infections, allowing for prompt intervention and reducing morbidity and mortality [51]. NLR can guide treatment decisions, especially in the context of anti-inflammatory therapies, by providing valuable information about the patient’s inflammatory status [52]. The Neutrophil-to-Lymphocyte Ratio (NLR) is emerging as a valuable and readily accessible biomarker for assessing disease severity, infection risk, and inflammatory status in Sickle Cell Anemia. Its integration into clinical practice has the potential to improve risk stratification, inform treatment decisions, and enhance the overall management of SCA patients. Further research is needed to establish standardized NLR thresholds and validate its role as a routine clinical tool in the management of SCA [53]. As our understanding of NLR in SCA continues to evolve, it offers a simple yet effective tool to help healthcare professionals address the unique challenges presented by this complex hematological disorder.

The dynamic nature of NLR allows for the monitoring of disease progression in SCA. Changes in NLR values over time can provide insights into the course of inflammation and its response to treatment. Serial measurements of NLR offer a non-invasive and cost-effective way to assess the effectiveness of therapeutic interventions and adjust treatment plans accordingly [54]. NLR has shown promise as a prognostic marker in SCA. Patients with persistently elevated NLR values may be at higher risk for adverse outcomes. Identifying individuals at greater risk allows healthcare providers to implement more aggressive management strategies and enhance patient outcomes [55].

Future Directions

The Neutrophil-to-Lymphocyte Ratio (NLR) has shown promise as a valuable biomarker in the management of Sickle Cell Anemia (SCA). However, there is still much to explore and uncover about its full potential and applications in this complex hematological disorder. This article discusses the future directions and potential research avenues for NLR in the context of SCA, including standardization, novel applications, and precision medicine [56]. One of the critical challenges in utilizing NLR in SCA is the lack of standardized NLR thresholds specific to this patient population. Future research should focus on establishing these thresholds to aid in consistent risk stratification and treatment decisions. Defining clinically relevant NLR values for various SCA subgroups (e.g., pediatric vs. adult patients, genotypic variations) could enhance its clinical utility [57].

More comprehensive longitudinal studies are needed to better understand the dynamic changes in NLR over time and their correlation with disease progression and clinical outcomes. These studies can help identify trends in NLR values in individual patients and offer insights into the long- term implications of inflammation in SCA. Longitudinal data can also aid in tracking the effectiveness of interventions and therapies aimed at reducing inflammation [58]. Future research should explore potential molecular and genetic associations with NLR in SCA. Investigating whether specific genetic markers or gene expression profiles are linked to variations in NLR could provide a deeper understanding of the underlying mechanisms of inflammation in SCA. Identifying genetic factors that influence NLR may open doors for targeted therapies [59].

NLR has the potential to guide personalized treatment strategies in SCA. Future research should delve into how NLR can be integrated into precision medicine approaches. This involves tailoring treatments based on an individual’s unique characteristics, including their NLR profile. Developing personalized treatment algorithms using NLR as a component could significantly improve the management of SCA [60]. The development of predictive models that incorporate NLR as a variable is a promising avenue for future research. These models could be used to forecast disease exacerbations, identify patients at high risk of complications, and guide clinical decision-making. By utilizing artificial intelligence and machine learning techniques, researchers can develop sophisticated predictive models that harness the power of NLR alongside other clinical and genetic data [61, 62, 63, 64].

Investigations into the impact of therapeutic interventions on NLR in SCA are warranted. Understanding how treatments, such as hydroxyurea, transfusion therapy, or anti-inflammatory agents, influence NLR can help refine treatment strategies and assess the efficacy of interventions designed to mitigate inflammation and its associated complications [65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75]. Future studies should focus on how NLR relates to patient-reported outcomes and quality of life in SCA. Exploring the connection between NLR and the burden of symptoms, pain, and overall well-being can provide a more holistic view of the patient experience and guide interventions aimed at improving their quality of life [76]. Neutrophil-to-Lymphocyte Ratio (NLR) holds promise as a valuable biomarker in SCA, but its full potential is yet to be realized [77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87]. Future research should concentrate on standardization, molecular and genetic associations, personalized treatment strategies, predictive modeling, therapeutic interventions, and patient-centered outcomes. A deeper understanding of NLR in SCA has the potential to transform the management of this challenging disease, improving the quality of care and outcomes for affected individuals [88, 89, 90].

Conclusion

The neutrophil-to-lymphocyte ratio is emerging as a valuable biomarker for assessing disease severity, infection risk, and inflammatory status in sickle cell anemia. The integration of NLR into clinical practice has the potential to improve risk stratification, guide treatment decisions, and enhance patient outcomes. Further research is warranted to fully elucidate its clinical applications in the context of SCA.

References

  1. Nongbri SR, Verma HK, Lakkakula BV, Patra PK (2017) Presence of atypical beta globin (HBB) gene cluster haplotypes in sickle cell anemia patients of India. Rev bras hematol hemoter 39: 180-182.
  2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO (2015) Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences 3(6B): 2244-2252.
  3. Obeagu EI (2020) Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences 5(2): 22-28.
  4. Obeagu EI (2018) Sickle Cell Anaemia: Haemolysis and Anemia. Int J Curr Res Chem Pharm Sci 5(10): 20-21.
  5. Muhammed E, Cooper J, Devito D, Mushi R, Del Pilar AM, et al. (2021) Elastic property of sickle cell anemia and sickle cell trait red blood cells. Journal of Biomedical Optics 26(9): 096502.
  6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Obeagu GU, et al. (2022) An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci 11(10): 84.
  7. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC (2014) Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int J Curr Microbiol App Sci 3(3): 1000-1005.
  8. Akpan IS, Uboh EE (2018) The pattern of morbidity in adult Nigerians with sickle cell anaemia: A tertiary healthcare setting perspective. Int J Health Sci Res 8: 18- 27.
  9. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene FK, et al. (2018) Sickle cell disease. Nature reviews Disease primers 4(1):1-22.
  10. Chen P, Zhou G, Lin J, Li L, Zeng Z, et al. (2020) Serum biomarkers for inflammatory bowel disease. Frontiers in Medicine 7: 123.
  11. Khurana K, Mahajan S (2023) Platelet indices and neutrophil: lymphocyte ratio as a predictive tool in acute sickle cell vaso-occlusive crisis: A study protocol. F1000Research 12: 1111.
  12. Duchesne JC, Tatum D, Jones G, Davis B, Robledo R, et al. (2017) Multi-institutional analysis of neutrophil- to-lymphocyte ratio (NLR) in patients with severe hemorrhage: a new mortality predictor value. Journal of Trauma and Acute Care Surgery 83(5): 888-893.
  13. Balandya E, Reynolds T, Obaro S, Makani J (2016) Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses. American journal of hematology 91(9): 938-946.
  14. Zhang L, Cao B, Hou Y, Wei Q, Ou R, et al. (2022) High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy. NPJ Parkinsons Dis 8(1): 11.
  15. Soder HE, Berumen AM, Gomez KE, Green CE, Suchting R, et al. (2020) Elevated neutrophil to lymphocyte ratio in older adults with cocaine use disorder as a marker of chronic inflammation. Clinical Psychopharmacology and Neuroscience 18(1): 32.
  16. Emokpae MA, Abdu A, Gwaram BA (2016) Neutrophil- to-lymphocyte, platelet-to-lymphocyte ratios and their association with atherogenic index of plasma in sickle cell nephropathy. Journal of Applied Hematology 7(1): 24.
  17. Zahorec R (2021) Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 122(7): 474-488.
  18. Holloway J, Neely C, Yuan X, Zhang Y, Ouyang J, et al. (2020) Evaluating the performance of a predictive modeling approach to identifying members at high-risk of hospitalization. J Med Econ 23(3): 228-234.
  19. Kilincalp S, Coban S, Akinci H, Hamamc M, Karaahmet F, et al. (2015) Neutrophil/lymphocyte ratio, platelet/ lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur j cancer prev 24(4): 328-333.
  20. Pistelli M, De LM, Ballatore Z, Caramanti M, Pagliacci A, et al. (2015) Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC cancer 15(1): 1-9.
  21. Syed AH, Khan T, Alromema N (2022) A Hybrid Feature Selection Approach to Screen a Novel Set of Blood Biomarkers for Early COVID-19 Mortality Prediction. Diagnostics 12(7): 1604.
  22. Derman BA, Macklis JN, Azeem MS, Sayidine S, Basu S, et al. (2017) Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC cancer 17: 1-6.
  23. Maharaj S, Chang S (2023) Clinical utility of neutrophil to lymphocyte ratio in sickle cell disease with vaso- occlusive crisis. Hematol Oncol Stem Cell Ther 16(1):79- 82.
  24. Pinato DJ, Stavraka C, Flynn MJ, Forster MD, Ocathail SM, et al. (2014) An inflammation-based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PloS one 9(1): e83279.
  25. Kurt A, Tosun MS, Altuntaş N (2022) Diagnostic accuracy of complete blood cell count and neutrophil-to- lymphocyte, lymphocyte-to-monocyte, and platelet-to- lymphocyte ratios for neonatal infection. Asian Biomed 16(1): 43-52.
  26. Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD (2019) The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann lab med 39(4): 345-357.
  27. Serra R, Ielapi N, Licastro N, Provenzano M, Andreucci M, et al. (2021) Neutrophil-to-lymphocyte ratio and platelet- to-lymphocyte ratio as biomarkers for cardiovascular surgery procedures: a literature review. Rev Recent Clin Trials 16(2): 173-179.
  28. Afari ME, Bhat T (2016) Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert rev cardiovasc ther 14(5): 573-577.
  29. Suppiah A, Malde D, Arab T, Hamed M, Allgar V, et al. (2013) The prognostic value of the neutrophil–lymphocyte ratio (NLR) in acute pancreatitis: identification of an optimal NLR. J Gastrointest Surg 17(4): 675-681.
  30. Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M (2021) Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma.” Review article. Ann hepatol 22: 100249.
  31. Kumarasamy C, Sabarimurugan S, Madurantakam RM, Lakhotiya K, Samiappan S, et al. (2019) Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. Medicine 98(24): e14834.
  32. Ng WW, Lam SM, Yan WW, Shum HP (2022) NLR, MLR, PLR and RDW to predict outcome and differentiate between viral and bacterial pneumonia in the intensive care unit. Sci Rep 12(1): 15974.
  33. Naess A, Nilssen SS, Mo R, Eide GE, Sjursen H (2017) Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever. Infection 45(3): 299-307.
  34. Li M, Xie L (2021) Correlation between NLR, PLR, and LMR and disease activity, efficacy assessment in rheumatoid arthritis. Evid Based Complement Alternat Med 21: 4433141.
  35. Guo X, Huang C, Xu J, Xu H, Liu L, et al. (2022) Gut microbiota is a potential biomarker in inflammatory bowel disease. Front Nutr 8: 818902.
  36. Jemaa AB, Salhi N, Othmen MB, Ali HB, Guissouma J, et al. (2022) Evaluation of individual and combined NLR, LMR and CLR ratio for prognosis disease severity and outcomes in patients with COVID-19. Int Immunopharmacol 109: 108781.
  37. Lang Y, Chu F, Shen D, Zhang W, Zheng C, et al. (2018) Role of inflammasomes in neuroimmune and neurodegenerative diseases: a systematic review. Mediators inflamm : 1549549.
  38. Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, et al. (2020) Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC med 18(1): 360.
  39. Sparks R, Rachmaninoff N, Hirsch DC, Bansal N, Lau WW, et al. (2023) Multiomics integration of 22 immune- mediated monogenic diseases reveals an emergent axis of human immune health. Res Sq: 2070975.
  40. Buonacera A, Stancanelli B, Colaci M, Malatino L (2022) Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int j mol sci 23(7): 3636.
  41. Losurdo A, Fernandes B, Torrisi R, Masci G, Agostinetto E, et al. (2020) Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice. Scientific Reports 10(1): 20100.
  42. Inusa BP, Hsu LL, Kohli N, Patel A, Ominu EK, et al. (2019) Sickle cell disease genetics, pathophysiology, clinical presentation and treatment. Int J Neonatal Screen 5(2): 20.
  43. Alenzi FQ, AlShaya DS (2019) Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi J Biol Sci 26(7):1377-1384.
  44. Reilly SM, Saltiel AR (2017) Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol 13(11): 633-643.
  45. Feng X, Li L, Wu J, Zhang L, Sun Z, et al. (2019) Complete blood count score model integrating reduced lymphocyte‐ monocyte ratio, elevated neutrophil‐lymphocyte ratio, and elevated platelet‐lymphocyte ratio predicts inferior clinical outcomes in adult T‐lymphoblastic lymphoma. Oncologist 24(11): e1123-1131.
  46. Alagbe AE, Olaniyi JA (2019) Pattern of neutrophil- lymphocyte ratio and platelet-lymphocyte ratio in sickle cell anemia patients at steady state and vaso-occlusive crisis. Journal of Applied Hematology 10(2): 45-50.
  47. Naess A, Nilssen SS, Mo R, Eide GE, Sjursen H (2017) Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever. Infection 45(3): 299-307.
  48. Mathavan A, Mathavan A, Mathavan M, Krekora U, Winer AJ, et al. (2023) Impact of genotype on clinical course in sickle cell disease and the utility of neutrophil- lymphocyte ratio: a ten-year single-institution experience. Expert Rev Hematol 16(9): 701-710.
  49. Wu Y, Chen Y, Yang X, Chen L, Yang Y (2016) Neutrophil- to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. International immunopharmacology 36: 94-99.
  50. Arginase C, Bio IS (2015) Case Report of Acute Myeloid Leukemia Secondary to Primary Myelofibrosis Treated With Azacitidine. haematologica haemat 100(s3): 84.
  51. Mas CF, Olea LJ, Parroquin MJA (2021) Sepsis in trauma: a deadly complication. Archives of medical research 52(8): 808-816.
  52. Clarke SJ, Chua W, Moore M, Kao S, Phan V, et al. (2011) Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther 90(3): 475-478.
  53. Efobi CC, Nri ECA, Madu CS, Ikediashi CC, Ejiofor O, et al. (2023) Neutrophil-Lymphocyte, Platelet-Neutrophil, and Platelet Lymphocyte Ratios as Indicators of Sickle Cell Anaemia Severity. Ethiopian Journal of Health Sciences 33(5): 821-830.
  54. Grant RW, Dixit VD (2015) Adipose tissue as an immunological organ. Obesity 23(3): 512-518.
  55. Sweet DR, Freeman ML, Zidar DA (2023) Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention. Pathog Immun 8(1): 17-50.
  56. Ercin U (2020) Oral Presentations Abstracts. Turk J Biochem 45(S2): 25.
  57. Silaghi CA, Lozovanu V, Georgescu CE, Georgescu RD, Susman S, et al. (2021) Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis. Front Endocrinol 12: 649522.
  58. Bar AV, Palmer J, Li L, Lai Y, Lu B, et al. (2017) Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. Clin Transl Oncol 19(6): 711-717.
  59. Vázquez MY, Rodríguezv CY, Dominguez BY, León AK, Miranda BD, et al. (2023) Peripheral Inflammation Links with the Severity of Clinical Phenotype in Spinocerebellar Ataxia 2. Movement Disorders :29359.
  60. Infante T, Del VL, Rimini RML, Padula S, Caso P, et al. (2020) Network medicine: a clinical approach for precision medicine and personalized therapy in coronary heart disease. J Atheroscler Thromb 27(4): 279-302.
  61. Zhu J, Jiao D, Zhao Y, Guo X, Yang Y, et al. (2021) Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients. Sci Rep 11(1): 1350.
  62. Yuan Q, Wang J, Peng Z, Zhou Q, Xiao X, et al. (2019) Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). J transl med 17(1): 86.
  63. Kachroo U, Zachariah S, Livingston A (2019) Rethinking safety profile of drugs for rheumatoid arthritis. Indian Journal of Rheumatology S2: S100.
  64. Vita F, Olaizola I, Amato F, Rae C, Marco S, et al. (2023) Heterogeneity of Cholangiocarcinoma Immune Biology. Cells 12(6): 846.
  65. Obeagu EI (2023) Depression in Sickle Cell Anemia: An Overlooked Battle. Int J Curr Res Chem Pharm Sci 10(10): 41-44.
  66. Obeagu EI, Obeagu GU (2023) Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research 6(1): 2768-0487.
  67. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU (2023) Hyperthyroidism in sickle cell anaemia. Int J Adv Res Biol Sci 10(3): 81-89.
  68. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC (2023) Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine 102(48): e36462.
  69. Njar VE, Ogunnaya FU, Obeagu EI (2023) Knowledge and Prevalence of the Sickle Cell Trait Among Undergraduate Students of The University of Calabar. Prevalence 10(8): 64-71.
  70. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B (2018) Expression of micro RNA 144 in sickle cell disease. Int J Curr Res Med Sci 4(3): 26-32.
  71. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU (2023) Anaemia in children under five years: African perspectives. Int J Curr Res Biol Med 1: 1-7.
  72. Obeagu EI (2018) Sickle cell anaemia Historical perspective Pathophysiology and Clinical manifestations. Int J Curr Res Chem Pharm Sci 5(11): 13-15.
  73. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in Pregnancy A Review. Int Res Med Health Sci 6(2): 10-13.
  74. Obeagu EI, Mohamod AH (2023) An update on Iron deficiency anaemia among children with congenital heart disease. Int J Curr Res Chem Pharm Sci 10(4): 45- 48.
  75. Edward U, Osuorji VC, Nnodim J, Obeagu EI (2022) Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital Owerri. Madonna University journal of Medicine and Health Sciences 2(1): 218-234.
  76. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, et al. (2023) Assessment of Factors Precipitating Sickle Cell Crises Among Under 5 Years Children Attending Sickle Cell Clinic of Murtala Muhammad Specialist Hospital Kano. J Bio Innov 12(2): 297-302.
  77. Obeagu EI (2018) Vaso occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci 4(11): 33- 35.
  78. Ifeanyi OE, Stella EI, Favour AA (2018) Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord 3(2): 1-2
  79. Buhari HA, Ahmad AS, Obeagu EI. (2023) Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. Applied Sciences 4(1).
  80. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, et al. (2015) Hepcidin and erythropoietin level in sickle cell disease. Journal of Advances in Medicine and Medical Research 8(3): 261-5.
  81. Obeagu EI (2023) Burden of Chronic Osteomylitis Review of Associatied Factors. Madonna University journal of Medicine and Health Sciences 3(1): 1-6.
  82. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, et al. (2015) Antioxidant Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences 2(1): 502-507.
  83. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences 3(2): 56-59.
  84. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO (2023) Sickle Cell Anaemia Current Burden in Africa. Int J Innov App Res 11(2): 12-14.
  85. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN (2014) Haematological parameters among sickle cell anemia patients state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture Umudike Abia State Nigeria. International Journal of Current Microbiology and Applied Sciences 3(3): 1000- 1005.
  86. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu G (2023) Obsterics characteristics that effect the newborn outcomes. Int J Adv Res Biol Sci 10(3): 134-143.
  87. Obeagu EI, Opoku D, Obeagu GU (2023) Burden of nutritional anaemia in Africa A Review. Int J Adv Res Biol Sci 10(2): 160-163.
  88. Ifeanyi E (2015) Erythropoietin Level in Sickle Cell Anaemia With Falciparum Malaria Infection in University Health Services Michael Okpara University of Agriculture Umudike Abia State Nigeria. Paripex Indian Journal of Research 4(6): 258-259.
  89. Ifeanyi OE, Stanley MC, Nwakaego OB (2014) Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture Umudike, Abia state Nigeria. Int J Curr Microbiol App Sci 3(3): 1046-1050.
  90. Ifeanyi EO, Uzoma GO (2020) Malaria and The Sickle Cell Trait Conferring Selective Protective Advantage to Malaria. J Clin Med Res 2(2): 1-4.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{emmanuel2024,
  title   = {Clinical Implications of Neutrophil-to-Lymphocyte Ratio in Sickle Cell Disease},
  author  = {Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu},
  journal = {Haematology International Journal},
  year    = {2024},
  volume  = {8},
  number  = {1},
  doi     = {10.23880/hij-16000242}
}
Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu (2024). Clinical Implications of Neutrophil-to-Lymphocyte Ratio in Sickle Cell Disease. Haematology International Journal, 8(1). https://doi.org/10.23880/hij-16000242
TY  - JOUR
TI  - Clinical Implications of Neutrophil-to-Lymphocyte Ratio in Sickle Cell Disease
AU  - Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu
JO  - Haematology International Journal
PY  - 2024
VL  - 8
IS  - 1
DO  - 10.23880/hij-16000242
ER  -